ImageVerifierCode 换一换
格式:PPT , 页数:26 ,大小:675KB ,
文档编号:3419705      下载积分:22 文币
快捷下载
登录下载
邮箱/手机:
温馨提示:
系统将以此处填写的邮箱或者手机号生成账号和密码,方便再次下载。 如填写123,账号和密码都是123。
支付方式: 支付宝    微信支付   
验证码:   换一换

优惠套餐
 

温馨提示:若手机下载失败,请复制以下地址【https://www.163wenku.com/d-3419705.html】到电脑浏览器->登陆(账号密码均为手机号或邮箱;不要扫码登陆)->重新下载(不再收费)。

已注册用户请登录:
账号:
密码:
验证码:   换一换
  忘记密码?
三方登录: 微信登录  
下载须知

1: 试题类文档的标题没说有答案,则无答案;主观题也可能无答案。PPT的音视频可能无法播放。 请谨慎下单,一旦售出,概不退换。
2: 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。
3: 本文为用户(三亚风情)主动上传,所有收益归该用户。163文库仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(点击联系客服),我们立即给予删除!。
4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
5. 本站仅提供交流平台,并不能对任何下载内容负责。
6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

版权提示 | 免责声明

1,本文(早老性痴呆药物研究进展课件.ppt)为本站会员(三亚风情)主动上传,163文库仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。
2,用户下载本文档,所消耗的文币(积分)将全额增加到上传者的账号。
3, 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(发送邮件至3464097650@qq.com或直接QQ联系客服),我们立即给予删除!

早老性痴呆药物研究进展课件.ppt

1、How to accelerate AD research 8/3/20222ContentsCurrent situation of AD1What are big companies doing 2Trends3Perspective48/3/202231 Current situation of ADvPopulation:37 million vCauses:too sophisticatedvMarket drugs:Tarcrine,Donepezil,Rivastigmine,Galanthamine,Huperzine,MemantinevSome social activit

2、ies may correlate with AD,but cannot delay the progress of AD8/3/20224Nature Reviews.2010.7:387-3988/3/202252 What are big companies doingvA big cake attracts a lot of big companies,attention,such as Pfizer,Elan,Merk,Novartis and so on8/3/20226BMC Medicine 2009,7:7 8/3/20227TramiprosatevALZHEMED(Neu

3、rochem Inc.)vThe Phase III trial did not show a beneficial effect on cognition or function,so the development program has been discontinued 8/3/20228Vaccines and antibodiesvAN-1792(Elan)the first-generation amyloid vaccine,Phase II trial was discontinued owing to the development of aseptic meningoen

4、cephalitis in 6%of the patientsvACC-001(Elan)prevent the induction of a toxic cellular immune response,in a Phase II clinical trialvBapineuzumab(Elan/Wyeth):Phase III,monoclonal antibodiesvImmunoglobulin IgIV:Phase III,polyclonal antibodies8/3/202298/3/202210RAGE InhibitorvAmyloid is known to bind t

5、o receptors for advanced glycated endproducts(RAGE)on the surface of cells and at the blood-brain barrier;this binding may contribute to inflammation and neuronal death.vPF-04494700:an orally bioavailable antagonist of RAGE,Phase II 8/3/202211-secretase inhibitorsvTarenflurbil:the enantiomer of the

6、non-steroidal anti-inflammatory drug flurbiprofen,modulates the activity of-secretase,failed in Phase III vSemagacestat:reduction of amyloid peptide generation in blood and cerebrospinal fluid of patients with AD treated with tolerable doses,in Phase III8/3/202212Tau aggregation inhibitorvRember(Met

7、hylene blue):a widely used histology dye,has been shown to interfere with tau aggregation.v Entering Phase III8/3/2022138/3/202214Microtubule stabilizervNAP(AL-108):derived from a natural neurotrophic protein,can be delivered to the central nervous system via intranasal administration.vmarkedly redu

8、ces tau phosphorylation,and preliminary human studies have been encouraging.Now it is in Phase II trial.8/3/202215Dimebon-Pfizerv Phase III trial(Dimebon and Donepezil):failed,but Pfizer now is launching another Phase III trial about dimebon with other AD drugs.NNN8/3/202216vPhase III trials of Gink

9、go biloba,NSAIDs,phenserine,statins,tarenflurbil,tramiprosate,and xaliproden have been completed,none of them demonstrating adequate efficacy.vPhase II trials of dimebon,huperzine A,intravenous immunoglobulin,and methylthioninium chloride were reported at 2008.vNineteen compounds are currently in Ph

10、ase II trials,and 3 compounds(AN1792,lecozotan SR,and SGS742)failed at this stage of development.8/3/2022173 TrendsvMultitarget Anti-Alzheimer AgentsvAD modelvfurther explore the causesvcoalition and cooperation8/3/202218Multitarget Anti-Alzheimer AgentsNovel Tacrine-8-Hydroxyquinoline Hybrids as Mu

11、ltifunctional Agents for the Treatment of Alzheimers Disease,with Neuroprotective,Cholinergic,Antioxidant,and Copper-Complexing Properties8/3/2022198/3/202220Bivalent-Carbolines as Potential Multitarget Anti-Alzheimer Agents8/3/202221AD modelvA platform to perform pharmacological evaluation of anima

12、l models of Alzheimers diseasevIn the future drug candidates may be directly used to animal models of Alzheimers disease8/3/202222Further explore the causesThe brain of AD patient likes a labyrinth 8/3/202223CooperationvWhile each of us is running into a stone wall with Alzheimers,what will we do ne

13、xt?vAllow researchers to study a larger pool of patients will help us see how the disease progresses,identify subgroups,and hopefully develop more sophisticated computer models that could save time and money developing drugs.8/3/2022244 PerspectivevWhile it is not possible to predict the success of

14、any individual program,one or more are likely to prove effective.vDespite disappointing results from recently completed Phase III trials of several novel compounds,the extent and breadth of activity at all phases of clinical development suggest that new pharmacotherapeutic options for the treatment

15、of AD will become available within the next decade.vIt seems reasonable to predict that in the not-too-distant future,a synergistic combination of agents will have the capacity to alter the neurodegenerative cascade and reduce the global impact of this devastating disease.8/3/202226Reference1 Michae

16、l S Rafii and Paul S Aisen.Recent developments in Alzheimers disease therapeutics.BMC Medicine 2009,7:7,1741-7-15.2 Yvonne Rook.Bivalent-Carbolines as Potential Multitarget Anti-Alzheimer Agents.J.Med.C.XXXX,Vol.XXX,NO.XX3 Mara Isabel Fern andez-Bachiller.Novel Tacrine-8-Hydroxyquinoline Hybrids as

17、Multifunctional Agents for the Treatment of Alzheimers Disease,with Neuroprotective,Cholinergic,Antioxidant,and Copper-Complexing Properties.J.Med.C.XXXX,XXX,000-000.4 Raymond T.Bartus&Reginald L.Dean III.Pharmaceutical treatment for cognitive deficits in Alzheimers disease and other neurodegenerati

18、ve conditions:exploring new territory using traditional tools and established maps.Psychopharmacology(2009)202:1536.5 Marwan N.Sabbagh.Drug Development for Alzheimers Disease:Where Are We Now and Where Are We Headed?.The American Journal of Geriatric Pharmacotherapy 2009,7(3):167-185.6 Martin Citron.Alzheimers disease:strategies for disease modification.Nature Reviews.2010.7:387-398

侵权处理QQ:3464097650--上传资料QQ:3464097650

【声明】本站为“文档C2C交易模式”,即用户上传的文档直接卖给(下载)用户,本站只是网络空间服务平台,本站所有原创文档下载所得归上传人所有,如您发现上传作品侵犯了您的版权,请立刻联系我们并提供证据,我们将在3个工作日内予以改正。


163文库-Www.163Wenku.Com |网站地图|